Total Lesion Score is calculated as the sum of component scores for erythema (E), scaling (S), and thickness (T) of the study-treated lesions taken together. Each component consists of ratings of 0=none, 1=mild, 2=moderate, 3=marked, and 4=severe such that total lesion score can vary in value from 0 to 12. A negative change from Baseline indicates improvement.

All participants who were randomized to treatment and had both a baseline visit and received at least one application of study drug were included in the ITT population. Overall number of participants analyzed are the participants with data available for analysis.

Lesion thickness was scored using a 5-point scale ranging from 0 to 4 where 0 is none or absent and 4 is severe lesion. A negative change from Baseline indicates improvement.

All participants who were randomized to treatment and had both a baseline visit and received at least one application of study drug were included in the ITT population. Overall number of participants analyzed are the participants with data available for analysis.

Lesion erythema was scored using a 5-point scale ranging from 0 to 4 where 0 is none or absent and 4 is severe lesion. A negative change from Baseline indicates improvement.

All participants who were randomized to treatment and had both a baseline visit and received at least one application of study drug were included in the ITT population. Overall number of participants analyzed are the participants with data available for analysis.

Lesion scaling was scored using a 5-point scale ranging from 0 to 4 where 0 is none or absent and 4 is severe lesion. A negative change from Baseline indicates improvement.

All participants who were randomized to treatment and had both a baseline visit and received at least one application of study drug were included in the ITT population. Overall number of participants analyzed are the participants with data available for analysis.

Lesion thickness was scored using a 5-point scale ranging from 0 to 4 where 0 is none or absent and 4 is severe lesion. A negative percent change from Baseline indicates improvement in lesion.

All participants who were randomized to treatment and had both a baseline visit and received at least one application of study drug were included in the ITT population. Overall number of participants analyzed are the participants with data available for analysis.

Lesion erythema was scored using a 5-point scale ranging from 0 to 4 where 0 is none or absent and 4 is severe lesion. A negative percent change from Baseline indicates improvement in lesion.

All participants who were randomized to treatment and had both a baseline visit and received at least one application of study drug were included in the ITT population. Overall number of participants analyzed are the participants with data available for analysis.

Lesion scaling was scored using a 5-point scale ranging from 0 to 4 where 0 is none or absent and 4 is severe lesion. A negative percent change from Baseline indicates improvement in lesion.

All participants who were randomized to treatment and had both a baseline visit and received at least one application of study drug were included in the ITT population. Overall number of participants analyzed are the participants with data available for analysis.

Lesion thickness was scored using a 5-point scale ranging from 0 to 4 where 0 is none or absent and 4 is severe lesion. Participants with individual lesion scores 0 (none) and 1 (mild) are reported in this outcome measure.

All participants who were randomized to treatment and had both a baseline visit and received at least one application of study drug were included in the ITT population.

The individual lesion scores were calculated individually for thickness, erythema, and scaling. Lesion erythema was scored using a 5-point scale ranging from 0 to 4 where 0 is none or absent and 4 is severe lesion. Participants with individual lesion scores 0 (none) and 1 (mild) are reported in this outcome measure. The LOCF method was used for analysis.

All participants who were randomized to treatment and had both a baseline visit and received at least one application of study drug were included in the ITT population.

The individual lesion scores were calculated individually for thickness, erythema, and scaling. Lesion scaling was scored using a 5-point scale ranging from 0 to 4 where 0 is none or absent and 4 is severe lesion. Participants with individual lesion scores 0 (none) and 1 (mild) are reported in this outcome measure. The LOCF method was used for analysis.

All participants who were randomized to treatment and had both a baseline visit and received at least one application of study drug were included in the ITT population.

The lesion areas were estimated based on the Rule of Nines method for the entire skin surface; psoriatic disease activity and the percent BSA were calculated for the treatable areas (i.e., areas that excluded the scalp, face, and intertriginous areas). The BSA is calculated as follows: BSA (m^²)=([Height(cm) x Weight(kg)]/3600 )^½. A negative change from Baseline indicates improvement.

All participants who were randomized to treatment and had both a baseline visit and received at least one application of study drug were included in the ITT population. Overall number of participants analyzed are the participants with data available for analysis.

The overall disease activity in the participants, a measure of the overall quality (erythema, scaling, and thickness) and extent (BSA) of plaques, was measured using the PGA. The PGA was an overall assessment of each participant's plaque psoriasis. The assessment was recorded using a 6-point scale ranging from 0 to 5 where 0 is 'Clear' (no evidence of disease) and 5 is 'very Severe' lesion. A negative change from Baseline indicates improvement. The ANCOVA method was used for analyses.

All participants who were randomized to treatment and had both a baseline visit and received at least one application of study drug were included in the ITT population. Overall number of participants analyzed are the participants with data available for analysis.

The overall disease activity in the participants, a measure of the overall quality (erythema, scaling, and thickness) and extent (BSA) of plaques, was measured using the PGA. The PGA was an overall assessment of each participant's plaque psoriasis. The assessment was recorded using a 6-point scale ranging from 0 to 5 where 0 indicates 'Clear' (no evidence of disease) and 5 indicates 'very Severe' lesion. A negative percent change indicates improvement. The ANCOVA method was used for analyses.

All participants who were randomized to treatment and had both a baseline visit and received at least one application of study drug were included in the ITT population. Overall number of participants analyzed are the participants with data available for analysis.

The overall disease activity in the participants, a measure of the overall quality (erythema, scaling, and thickness) and extent (BSA) of plaques, was measured using the PGA. The PGA was an overall assessment of each participant's plaque psoriasis. The assessment was recorded using a 6-point scale ranging from 0 to 5 where 0 indicates 'Clear' (no evidence of disease) and 5 indicates 'very Severe' lesion. Participants with individual lesion scores 0 (clear) and 1 (almost clear) are reported in this outcome measure.

All participants who were randomized to treatment and had both a baseline visit and received at least one application of study drug were included in the ITT population.

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring [lower extremities, trunk (including stomach, chest, back), upper extremities, head]; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by scale 0 (none) to 4 (severe). Final PASI is the sum of severity score for each area multiplied coverage for each section multiplied by area score weight of section (lower extremities: 0.4, trunk: 0.3, upper extremities: 0.2, head: 0.1). A negative change from baseline indicates improvement. The ANCOVA method was used for analyses.

All participants who were randomized to treatment and had both a baseline visit and received at least one application of study drug were included in the ITT population. Overall number of participants analyzed are the participants with data available for analysis.

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring [lower extremities, trunk (including stomach, chest, back), upper extremities, head]; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by scale 0 (none) to 4 (severe). Final PASI is the sum of severity score for each area multiplied by coverage for each section multiplied by area score weight of section (lower extremities: 0.4, trunk: 0.3, upper extremities: 0.2, head: 0.1). A percent negative change from baseline indicates improvement in disease. The ANCOVA method was used for analyses.

All participants who were randomized to treatment and had both a baseline visit and received at least one application of study drug were included in the ITT population. Overall number of participants analyzed are the participants with data available for analysis.

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring [lower extremities, trunk (including stomach, chest, back), upper extremities, head]; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by scale 0 (none) to 4 (severe). Final PASI is the sum of severity score for each area* multiplied by coverage for each section* multiplied by area score weight of section (lower extremities: 0.4, trunk: 0.3, upper extremities: 0.2, head: 0.1). A negative percent change from Baseline indicates improvement. Data for Day 84 was imputed using the LOCF method.

All participants who were randomized to treatment and had both a baseline visit and received at least one application of study drug were included in the ITT population. Overall number analyzed are the participants with percent treatable BSA of at least 10%.

All participants who used at least one application of study medication, and provided at least one plasma sample were considered potentially evaluable for the pharmacokinetic (PK)/ pharmacodynamic (PD) population.